Here’s How EUA for Celltrion Affects Indonesia’s COVID-19 Response

By Editorial Team 21/07/2021
army fighting coronavirus
Summary

Celltrion, a drug manufacturer from South Korea, claims to have secured an emergency use authorization (EUA) from the Food and Drug Monitoring Agency (BPOM) for a drug called Regkirona. The Korea Biomedical Review reported that the permit was out on July 17, 2021. Regkirona reportedly showed efficacy in treating adult COVID-19 patients with mild and moderate symptoms.

The company hopes that the Regkirona antibody treatment can curb COVID-19 transmissions in Indonesia. Celltrion has confirmed its efficacy in neutralizing the Delta variant of COVID-19 through animal tests. "Regkirona has proven its efficacy through global clinical and quality data. The authorization is expected to speed up Regkirona’s export negotiations," a company’s official said.

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

Sign up
Log in
What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.